First Line Treatment In Metastatic Renal Cell Cancer

Metastatic renal cell carcinoma is cancer in your kidneys that has spread to other parts of your body.

First line treatment in metastatic renal cell cancer.

The incidence of renal cell carcinoma rcc has steadily risen over the past 10 years and accounts for 2 3 of all adult malignancies 1 metastatic rcc mrcc is associated with a poor prognosis. 1 however 30 to 40 of patients will develop metastatic disease after definitive treatment of localized disease 2 3 4 although for localized disease surgical resection with curative intent has been the standard approach for metastatic rcc mrcc. J clin oncol. Pal e christopher j d.

A network meta analysis provides an approach for quantitative analysis. The treatment of metastatic renal cell carcinoma has been revolutionized twice in the past 12 years by data showing that vascular. Hahn a zachary klaassen b c neeraj agarwal a benjamin haaland a john esther a xiang y. Randomized phase ii trial of first line treatment with sorafenib versus interferon alfa 2a in patients with metastatic renal cell carcinoma.

First line treatment of metastatic renal cell carcinoma. To indirectly compare the efficacy and safety of first line treatments for mrcc in the intention to treat itt population and by clinical risk group. Globally the incidence and mortality of renal cell carcinoma rcc has corresponded to 403 000 new cases and 175 000 deaths. A systematic review and network meta analysis author links open overlay panel andrew w.

Guidelines and randomized trial reports usually do not elucidate the decision criteria for the different treatment options. The therapeutic approach for renal cell carcinoma is guided by the probability of cure which i. With the advent of targeted therapies many treatment options in the first line setting of metastatic clear cell renal cell carcinoma mccrcc have emerged. It s also called stage iv renal cell cancer.

The relatively rapid evolution and rate of approval for metastatic renal cell carcinoma mrcc treatments have created a degree of complexity and ambiguity to first line treatment choice. Ye d xuechen wang a sumanta k. The first 100 words appear below. This article has no abstract.

Many recent first line clinical trials for mrcc employed the international metastatic rcc database consortium criteria to aid in risk stratification of patients. Historically 5 year survival was around 8 but that is rapidly improving 2 for many years the only treatment for mrcc approved by the us food and drug administration fda was high dose interleukin.